References of "European Heart Journal"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDeferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial
Zimmermann, Frederik M.; Ferrara, Angela; Johnson, Nils P. et al

in European Heart Journal (2015), 36

Deferral of PCI of a functionally non-significant stenosis is associated with a favourable very long-term follow-up without signs of late ‘catch-up’ phenomenon.

Detailed reference viewed: 34 (9 ULg)
Full Text
Peer Reviewed
See detailClinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium.
Stone, Gregg W.; Vahanian, Alec S.; Adams, David H. et al

in European heart journal (2015), 36(29), 1851-77

Mitral regurgitation (MR) is one of the most prevalent valve disorders and has numerous aetiologies, including primary (organic) MR, due to underlying degenerative/structural mitral valve (MV) pathology ... [more ▼]

Mitral regurgitation (MR) is one of the most prevalent valve disorders and has numerous aetiologies, including primary (organic) MR, due to underlying degenerative/structural mitral valve (MV) pathology, and secondary (functional) MR, which is principally caused by global or regional left ventricular remodelling and/or severe left atrial dilation. Diagnosis and optimal management of MR requires integration of valve disease and heart failure specialists, MV cardiac surgeons, interventional cardiologists with expertise in structural heart disease, and imaging experts. The introduction of transcatheter MV therapies has highlighted the need for a consensus approach to pragmatic clinical trial design and uniform endpoint definitions to evaluate outcomes in patients with MR. The Mitral Valve Academic Research Consortium is a collaboration between leading academic research organizations and physician-scientists specializing in MV disease from the United States and Europe. Three in-person meetings were held in Virginia and New York during which 44 heart failure, valve, and imaging experts, MV surgeons and interventional cardiologists, clinical trial specialists and statisticians, and representatives from the U.S. Food and Drug Administration considered all aspects of MV pathophysiology, prognosis, and therapies, culminating in a 2-part document describing consensus recommendations for clinical trial design (Part 1) and endpoint definitions (Part 2) to guide evaluation of transcatheter and surgical therapies for MR. The adoption of these recommendations will afford robustness and consistency in the comparative effectiveness evaluation of new devices and approaches to treat MR. These principles may be useful for regulatory assessment of new transcatheter MV devices, as well as for monitoring local and regional outcomes to guide quality improvement initiatives. [less ▲]

Detailed reference viewed: 115 (0 ULg)
Full Text
Peer Reviewed
See detailThe year in cardiology 2014: valvular heart disease.
Pierard, Luc ULg; Vahanian, Alec

in European heart journal (2015)

Detailed reference viewed: 28 (2 ULg)
Full Text
Peer Reviewed
See detailCardioPulse: cardiac imaging of adult cancer patients on chemotherapy.
Galderisi, Maurizio; Lancellotti, Patrizio ULg

in European heart journal (2015), 36(15), 889-90

Detailed reference viewed: 32 (0 ULg)
Full Text
Peer Reviewed
See detail2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Elliott, Perry M.; Anastasakis, Aris; Borger, Michael A. et al

in European heart journal (2014), 35(39), 2733-79

Detailed reference viewed: 38 (0 ULg)
Full Text
Peer Reviewed
See detail2014 ESC/ESA Guidelines on Non-cardiac Surgery: Cardiovascular Assessment and Management.
Kristensen, Steen Dalby; Knuuti, Juhani; Saraste, Antti et al

in European Heart Journal (2014), 35(35), 2383-431

Detailed reference viewed: 24 (0 ULg)
Full Text
Peer Reviewed
See detailTreatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study
Linke, Axel; Wenaweser, Peter; Gerckens, Ulrich et al

in European Heart Journal (2014)

Aim Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following ... [more ▼]

Aim Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following implantation of a self-expanding transcatheter aortic valve system in a fully monitored, multi-centre ‘real-world’ patient population in highly experienced centres. Methods and results Patients with severe aortic stenosis at a higher surgical risk inwhomimplantation of theCoreValve Systemwas decided by the Heart Teamwere included. Endpointswere a composite of major adverse cardiovascular and cerebrovascular events (MACCE; all-cause mortality, myocardial infarction, stroke, or reintervention) and mortality at 30 days and 1 year. Endpoint- related eventswere independently adjudicated based on Valve AcademicResearch Consortiumdefinitions.Atotal of 1015 patients [mean logistic EuroSCORE 19.4+12.3% [median (Q1,Q3), 16.0% (10.3, 25.3%)], age 81+6 years] were enrolled. Implantation of the CoreValve System led to a significant improvement in haemodynamics and an increase in the effective aortic valve orifice area. At 30 days, theMACCErate was 8.0% (95% CI: 6.3–9.7%), all-cause mortalitywas 4.5% (3.2–5.8%), cardiovascular mortality was 3.4% (2.3–4.6%), and the rate of stroke was 3.0% (2.0–4.1%). The lifethreatening or disabling bleeding rate was 4.0% (2.8–6.3%). The 12-month rates of MACCE, all-cause mortality, cardiovascular mortality, and stroke were 21.2% (18.4–24.1%), 17.9% (15.2–20.5%), 11.7% (9.4–14.1%), and 4.5% (2.9–6.1%), respectively. The 12-month rates of all-cause mortality were 11.1, 16.5, and 23.6% among patients with a logistic Euro- SCORE ≤10%, EuroSCORE 10–20%, and EuroSCORE .20% (P , 0.05), respectively. Conclusion The ADVANCE study demonstrates the safety and effectiveness of the CoreValve System with low mortality and stroke rates in higher risk real-world patients with severe aortic stenosis. [less ▲]

Detailed reference viewed: 100 (2 ULg)
Full Text
Peer Reviewed
See detailRemote ischaemic pre-conditioning in cardiac surgery: benefit or not?
Kolh, Philippe ULg

in European heart journal (2014), 35(3), 141-3

Detailed reference viewed: 10 (0 ULg)